Sign in
ALMS Stock Price, Chart, Stats & News
Alumis Inc. Common Stock
Save
2.54B
Market cap
–
Current P/E
–
Forward P/E
ALMS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 96.40% |
Operating margin | -1837.44% |
Pretax margin | -1047.34% |
Net margin | -1011.75% |
Effective tax rate | 3.40% |
ROA | -59.07% |
ROE | -72.65% |
D/E | 0.12x |
Interest coverage ratio | – |
ALMS valuation
P/E | – |
P/S | 126.98x |
P/B | 8.62x |
P/CF | -7.03x |
P/FCF | -8.25x |
P/OCF | -7.03x |
PEG | -0.48x |
EV multiple | -7.50x |
About
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
Similar securities
Based on sector and market capitalization
Report issue